Viroclinics-DDL changes name to Cerba Research

Viroclinics-DDL a world-leading vaccine and antiviral specialty laboratory providing research and clinical trial solutions rooted in virology, proudly announces changing its name to Cerba Research as of the 1st of April 2024.

Chronic ear infections linked to lasting brain and language deficits in children

Ear infections are a common childhood experience, but a new study suggests parents should take these infections seriously to preserve their children’s language development.

January 4, 2024

Fractyl pitches potential of GLP-1 gene therapy, but pushes clinical trials back to 2025

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 24, 2024

Unique bacteria colonize the gut shortly after birth and make serotonin to educate gut immune cells

A recent study revealed that neonatal gut bacteria produce serotonin and down-regulate monoamine oxidase A (MOA) to limit serotonin breakdown, thereby promoting immune tolerance.

March 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.